Canadian Pharma Company Targets Market with Domestic Generic Ozempic
A newly-established Canadian pharmaceutical firm, Vimy Pharma, is preparing to enter the market with a generic version of Ozempic, one of the world’s most recognized prescription medications.
“Our focus is entirely on this drug,” said David Suchon, co-founder of the Toronto-based company, which was founded in 2024 by two former executives of Novo Nordisk.
The company’s initiative emphasizes Canada’s ability to manufacture pharmaceuticals domestically, especially amid global uncertainties and fluctuating tariffs.
The active ingredient in Ozempic and Wegovy, semaglutide, lost data protection in January, according to Health Canada. This change allows generic manufacturers to produce lower-cost versions of the drug, increasing accessibility for patients.
Vimy Pharma aims to leverage rising Canadian patriotism, which has intensified due to recent trade tensions with the United States. By producing a locally-made, affordable version of semaglutide, the company hopes to appeal to both national pride and cost-conscious consumers.
NEWS DESK
PRESS UPDATE